Glutathione Sourcing Vocabulary and Catalogue Query Orthography: A Research Review of Tripeptide Redox Biochemistry, GSH/GSSG Cycle Pharmacology and the Resolution of "glutathione 1500mg peptide", "peptides glutathione" and "l glutathione 1500mg" Labels

By the Peptide Insider Research Desk

The query string glutathione 1500mg peptide appears across multiple research-supply catalogues, yet the label conflates a fill-mass descriptor with a compound whose identity is rooted in endogenous redox biochemistry rather than synthetic peptide design. This review resolves that label — and its orthographic neighbours peptides glutathione, glutathione 1500 mg, l glutathione 1500mg, what is glutathione peptide and 1500 mg glutathione — by mapping each token to the underlying γ-L-glutamyl-L-cysteinyl-glycine (GSH) identity, then examining the redox cycle, enzymatic cofactor roles and bioavailability pharmacokinetics that define the molecule in a research context. All content below is strictly for research reference; not for human or veterinary use.

Catalogue Query Orthography and Sourcing Vocabulary Crosswalk

The table below classifies every uncovered CSV query string by token anatomy and research-use-only (RUO) scope status. Fill-mass tokens (1500mg, 1500 mg) are Recorded-as-nomenclature — they describe vial net content, not a protocol recommendation. Dosage-intent strings are Declined per RUO policy.

Structural Identity and the γ-Peptide Bond

Glutathione is a tripeptide whose three residues — L-glutamate, L-cysteine and glycine — are joined by two peptide bonds, one of which is non-standard. The bond linking glutamate to cysteine forms through the γ-carboxyl group of glutamate rather than the conventional α-carboxyl group, producing a γ-peptide linkage that confers resistance to cleavage by typical intracellular aminopeptidases and carboxypeptidases [1,2]. This structural feature explains why GSH accumulates at millimolar concentrations (1–10 mM) in the cytosol while most other peptides are rapidly degraded [2]. The reactive thiol (-SH) on the cysteine residue is the functional epicentre of the molecule, donating electrons to reactive oxygen species (ROS) and serving as the nucleophilic site for enzymatic conjugation reactions [1,3].

The GSH/GSSG Redox Cycle: Mechanism and Enzymatic Regulation

The glutathione redox cycle maintains cellular reductive capacity through a tightly coupled enzymatic loop. In the oxidative arm, glutathione peroxidase (GPx) catalyses the reduction of hydrogen peroxide (H₂O₂) and lipid hydroperoxides to water and alcohols, oxidising two molecules of GSH to form glutathione disulfide (GSSG) in the process [1,3]. In the reductive arm, glutathione reductase (GR) regenerates GSH from GSSG using NADPH supplied by the pentose phosphate pathway as the electron donor [2,3]. Under homeostatic conditions the cytosolic GSH/GSSG ratio exceeds 100:1; a declining ratio is a quantitative biomarker of oxidative stress and has been documented in preclinical models of ischaemia-reperfusion injury, hepatotoxicity and neurodegeneration [3,4].

Beyond peroxide detoxification, GSH serves as a cosubstrate for the glutathione S-transferase (GST) superfamily, which conjugates electrophilic xenobiotics and endogenous toxicants to the cysteinyl thiol for subsequent mercapturic acid pathway excretion — the Phase II detoxification route [5,6]. GST-mediated conjugation is the principal mechanism by which cells neutralise alkylating agents, epoxides and α,β-unsaturated carbonyls [6].

Nrf2-ARE Axis and Transcriptional Regulation of GSH Homeostasis

GSH biosynthesis is transcriptionally regulated by the Keap1-Nrf2-ARE (antioxidant response element) axis. Under basal conditions the E3-ubiquitin-ligase adaptor Keap1 sequesters the transcription factor Nrf2 in the cytoplasm and targets it for proteasomal degradation [7,8]. Oxidative or electrophilic stress triggers S-glutathionylation of critical cysteine residues on Keap1 (notably Cys151, Cys273 and Cys288), disrupting the Keap1–Nrf2 interaction and permitting Nrf2 nuclear translocation [8]. Nuclear Nrf2 then heterodimerises with small Maf proteins and binds ARE sequences upstream of genes encoding GCL catalytic and modifier subunits (GCLC/GCLM), glutathione synthetase (GSS) and glutathione reductase (GR), thereby upregulating the entire biosynthetic and recycling apparatus [2,7]. This feedback loop — where GSH status itself modulates the Keap1 redox sensor — constitutes a self-correcting homeostatic circuit documented in hepatocyte, epithelial and neuronal cell models [7,8].

S-Glutathionylation as a Redox Signalling Mechanism

Beyond its role as a bulk antioxidant, GSH participates in post-translational redox signalling through S-glutathionylation — the reversible formation of a mixed disulfide between the GSH cysteinyl thiol and an exposed protein cysteine residue [9]. This modification protects critical protein thiols from irreversible oxidation (sulfinic/sulfonic acid) during oxidative bursts and simultaneously modulates enzyme activity, serving as a redox-sensitive "on/off" switch [9]. Notable substrates include NF-κB p65, IκB kinase β (IKKβ), actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [9,10]. In pulmonary epithelial cell models, GSTP-mediated S-glutathionylation of IKKβ suppressed NF-κB-driven pro-inflammatory gene expression, linking GSH status to inflammatory signalling regulation [10].

Preclinical Evidence Summary

Bioavailability Pharmacokinetics: From Standard Powder to Advanced Delivery

Standard oral glutathione exhibits poor systemic bioavailability: an early pharmacokinetic study demonstrated negligible circulating GSH change following a single 3 g oral dose, attributable to intestinal and hepatic γ-glutamyltransferase (GGT) hydrolysis [15]. A six-month RCT nevertheless showed that daily oral GSH at 250 mg and 1000 mg increased erythrocyte and lymphocyte GSH stores dose-dependently, with reduced GSSG/GSH ratios [4]. Liposomal encapsulation further enhanced uptake: a one-month pilot RCT reported whole-blood GSH increases of 40% and PBMC GSH increases of 100% following 500–1000 mg/d liposomal GSH [11]. A 2026 crossover trial comparing micellar (LipoMicel) versus standard glutathione demonstrated four-fold higher dose-normalised iAUC₀₋₂₄ for the micellar formulation [14], and a separate 2026 ODF trial observed superior plasma GSH concentrations at 4 and 6 hours versus conventional tablets [13].

GSH Depletion and Neurodegenerative Research Models

Glutathione depletion is documented as an early event in preclinical models of Parkinson's disease, preceding dopaminergic neuron loss in the substantia nigra [3,12]. In astrocyte-neuron co-culture systems, GSH is synthesised primarily in astrocytes and exported via the γ-GT/dipeptidase pathway to supply neuronal cysteine for intraneuronal GSH synthesis; disruption of this shuttle impairs mitochondrial Complex I activity and sensitises neurons to oxidative insults [12]. The substantia nigra GSH/GSSG ratio has consequently been proposed as a redox biomarker for disease staging in translational neurodegeneration research [3].

Where to Source Glutathione for Research

Research-grade glutathione (reduced, L-form) is available from multiple specialist peptide and biochemical suppliers. Short Chain Aminos stocks lyophilised GSH with certificate-of-analysis documentation verifying purity and optical rotation. Additional research-supply catalogues include BioPep, Catalyst Research and Apex Research Services. Investigators should confirm the reduced (GSH) versus oxidised (GSSG) redox state on the CoA, verify residual solvent and endotoxin specifications, and request HPLC chromatograms to validate identity and purity prior to experimental use. No vendor referenced herein has been assessed or endorsed by this publication.

Frequently Asked Questions

What is glutathione peptide?

Glutathione (GSH) is an endogenous tripeptide composed of L-glutamate, L-cysteine and glycine linked by a γ-peptide bond (γ-L-glutamyl-L-cysteinyl-glycine, CAS 70-18-8, MW 307.32). It serves as the principal low-molecular-weight thiol antioxidant in mammalian cells, functioning as a cofactor for glutathione peroxidase (GPx) and glutathione S-transferase (GST) enzyme families [1,2]. Research catalogues list it as a tripeptide, distinct from longer-chain synthetic peptides.

What does "glutathione 1500mg peptide" mean in research catalogues?

The label glutathione 1500mg peptide designates a catalogue line item containing 1,500 milligrams of reduced L-glutathione lyophilised powder intended for in vitro research use. The "1500mg" token is a fill-mass descriptor specifying net content per vial; it does not indicate a protocol recommendation [4]. Researchers should verify certificate-of-analysis purity and confirm the reduced (GSH) versus oxidised (GSSG) redox state before use in cell-culture or biochemical assays.

What is the GSH to GSSG ratio and why does it matter in redox research?

The GSH/GSSG ratio is a quantitative biomarker of cellular redox status. Under homeostatic conditions the cytosolic ratio exceeds 100:1 in favour of reduced GSH [3]. A declining ratio indicates oxidative stress and has been observed in preclinical models of neurodegeneration, hepatotoxicity and ischaemia-reperfusion injury [3,4,12].

What does "l glutathione 1500mg" refer to in peptide sourcing?

The query l glutathione 1500mg specifies the L-enantiomer form of reduced glutathione at a 1,500 mg fill mass. The "L" prefix confirms the physiological stereoisomer (L-glutamate, L-cysteine, glycine) [2]. Research-grade materials are typically supplied as lyophilised powder with CoA documentation of optical rotation, residual solvent content and peptide purity.

How does glutathione relate to other research peptides in catalogues?

Glutathione is a naturally occurring tripeptide (three amino acid residues) and occupies the shortest chain-length category in peptide catalogues alongside KPV (α-MSH 11-13 fragment). Unlike synthetic research peptides such as BPC-157 (15-mer) or TB-500 (43-mer), GSH is endogenously synthesised by glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS) in virtually all mammalian cell types [1,2].

Works Cited

1. Métayer S et al. "Mechanisms through which sulfur amino acids control glutathione metabolism." Pathol Biol (Paris). 1996;44(1):66-72. PMID: 8734304.
2. Lu SC. "Regulation of glutathione synthesis." Mol Aspects Med. 2009;30(1-2):42-59. PMID: 18601945.
3. Forman HJ, Zhang H, Rinna A. "Glutathione: overview of its protective roles, measurement, and biosynthesis." Mol Aspects Med. 2009;30(1-2):1-12. PMC: PMC2696075.
4. Richie JP Jr et al. "Randomized controlled trial of oral glutathione supplementation on body stores of glutathione." Eur J Nutr. 2015;54(2):251-263. PMID: 24791752.
5. Townsend DM, Tew KD, Tapiero H. "The importance of glutathione in human disease." Biomed Pharmacother. 2003;57(3-4):145-155. PMID: 12818476.
6. Townsend DM, Tew KD. "The role of glutathione-S-transferase in anti-cancer drug resistance." Oncogene. 2003;22(47):7369-7375. PMID: 14576844.
7. Nrf2-ARE axis: Ma Q. "Role of Nrf2 in oxidative stress and toxicity." Annu Rev Pharmacol Toxicol. 2013;53:401-426. PMC: PMC4680839.
8. Li Y et al. "Glutathione induces Keap1 S-glutathionylation and mitigates oscillating glucose-induced β-cell dysfunction." Antioxidants. 2024;13(4):400. PMID: 38671848.
9. Dalle-Donne I et al. "S-glutathionylation in protein redox regulation." Free Radic Biol Med. 2007;43(6):883-898. PMID: 17697933.
10. Aesif SW et al. "Glutathione S-transferase pi modulates NF-κB activation and pro-inflammatory responses in lung epithelial cells." Redox Biol. 2016;8:375-382. PMID: 27058114.
11. Sinha R et al. "Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function." Eur J Clin Nutr. 2018;72(1):105-111. PMID: 28853742.
12. Dringen R. "Metabolism and functions of glutathione in brain." Prog Neurobiol. 2000;62(6):649-671. PMID: 10880854.
13. Orally dissolving film versus tablet glutathione pharmacokinetics. Eur J Pharm Biopharm. 2026. PMID: 42392376.
14. Micellar glutathione (LipoMicel) crossover pharmacokinetic trial. Antioxidants. 2026;15(3):354. DOI: 10.3390/antiox15030354.
15. Witschi A et al. "The systemic availability of oral glutathione." Eur J Clin Pharmacol. 1992;43(6):667-669. PMID: 1362956.

This article is provided strictly for research reference; not for human or veterinary use. No vendor referenced herein has been assessed or endorsed by this publication. Glutathione materials described are intended solely for qualified in vitro and preclinical research under appropriate institutional oversight.